Decera Clinical Education Oncology Podcast

Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions

Episode Summary

In this episode, 2 experts discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including the clinical impact of first-generation therapies and challenges related to resistance. They also explore emerging next-generation inhibitors and combination strategies that may expand treatment options and improve patient outcomes.

Episode Notes

In this episode, Dr Paz-Ares and Dr Christine Bestvina discuss the evolving role of KRAS G12C inhibitors in non-small-cell lung cancer (NSCLC), including:

• Clinical outcomes and limitations of first-generation KRAS G12C inhibitors
• Key unmet needs, including primary and acquired resistance
• Emerging strategies, including next-generation inhibitors and combination approaches with chemotherapy and immunotherapy

Presenters:

Luis Paz-Ares, MD, PhD
Head of Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor, Universidad Complutense de Madrid
Madrid, Spain

Christine Bestvina, MD
Associate Professor
University of Chicago Medicine
Division of Medicine
Section of Hematology/Oncology
University of Chicago Medicine
Chicago, Illinois

Link to full program:
https://bit.ly/4rhoUuN

Get access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify.